Boehringer Ingelheim BioXcellence and Sutro Biopharma (STRO) announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture ...
For patients with FRalpha;-expression levels of greater than or equal to 50.0%, treatment with farletuzumab ecteribulin led to an ORR of 22.2% (4 out of 18 patients) in Cohort 1 and 52.6% (10 out of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback